Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated
Encouraging data were presented for FGF19-positive tumours and those with worse hepatic function, performance status or advanced vascular invasion
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations
Recent research indicates that older age remains a barrier to accessing optimal treatment, despite a growing number of patients over 70 with ovarian and endometrial tumours
Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer
An analysis of the BEATcc trial showed that PD-L1 is not a robust biomarker for response to treatment
The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.